1887
  1. Home
  2. Eurosurveillance
  3. Volume 28, Issue 48, 30/Nov/2023
  4. Article
Research Open Access
Like 0
Download

Abstract

Background

Understanding the relative vaccine effectiveness (rVE) of new COVID-19 vaccine formulations against SARS-CoV-2 infection is a public health priority. A precise analysis of the rVE of monovalent and bivalent boosters given during the 2022 spring-summer and autumn-winter campaigns, respectively, in a defined population remains of interest.

Aim

We assessed rVE against hospitalisation for the spring-summer (fourth vs third monovalent mRNA vaccine doses) and autumn-winter (fifth BA.1/ancestral bivalent vs fourth monovalent mRNA vaccine dose) boosters.

Methods

We performed a prospective single-centre test-negative design case–control study in ≥ 75-year-old people hospitalised with COVID-19 or other acute respiratory disease. We conducted regression analyses controlling for age, sex, socioeconomic status, patient comorbidities, community SARS-CoV-2 prevalence, vaccine brand and time between baseline dose and hospitalisation.

Results

We included 682 controls and 182 cases in the spring-summer booster analysis and 572 controls and 152 cases in the autumn-winter booster analysis. A monovalent mRNA COVID-19 vaccine as fourth dose showed 46.6% rVE (95% confidence interval (CI): 13.9–67.1) vs those not fully boosted. A bivalent mRNA COVID-19 vaccine as fifth dose had 46.7% rVE (95% CI: 18.0–65.1), compared with a fourth monovalent mRNA COVID-19 vaccine dose.

Conclusions

Both fourth monovalent and fifth BA.1/ancestral mRNA bivalent COVID-19 vaccine doses demonstrated benefit as a booster in older adults. Bivalent mRNA boosters offered similar protection against hospitalisation with Omicron infection to monovalent mRNA boosters given earlier in the year. These findings support immunisation programmes in several European countries that advised the use of BA.1/ancestral bivalent booster doses.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2023.28.48.2300173
2023-11-30
2024-04-27
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2023.28.48.2300173
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/28/48/eurosurv-28-48-4.html?itemId=/content/10.2807/1560-7917.ES.2023.28.48.2300173&mimeType=html&fmt=ahah

References

  1. Joint Committee on Vaccination and Immunisation. Joint Committee on Vaccination and Immunisation (JCVI) statement on COVID-19 vaccinations in 2022: 21 February 2022. London: Department of Health and Social Care; 2022. Available from: https://www.gov.uk/government/publications/joint-committee-on-vaccination-and-immunisation-statement-on-covid-19-vaccinations-in-2022/joint-committee-on-vaccination-and-immunisation-jcvi-statement-on-covid-19-vaccinations-in-2022-21-february-2022
  2. Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infect Dis. 2022;22(8):1131-41.  https://doi.org/10.1016/S1473-3099(22)00271-7  PMID: 35550261 
  3. Møller Kirsebom FC, Andrews N, Stowe J, Groves N, Chand M, Ramsay M, et al. Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England. Lancet Reg Health Eur. 2022;23:100537.  https://doi.org/10.1016/j.lanepe.2022.100537  PMID: 36381141 
  4. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022;376:e069761.  https://doi.org/10.1136/bmj-2021-069761  PMID: 35264324 
  5. Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet. 2022;399(10327):814-23.  https://doi.org/10.1016/S0140-6736(22)00089-7  PMID: 35131043 
  6. Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ. 2021;374:n1943.  https://doi.org/10.1136/bmj.n1943  PMID: 34417165 
  7. Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C, et al. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nat Med. 2022;28(4):831-7.  https://doi.org/10.1038/s41591-022-01699-1  PMID: 35045566 
  8. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022;28(5):1063-71.  https://doi.org/10.1038/s41591-022-01753-y  PMID: 35189624 
  9. Britton A, Fleming-Dutra KE, Shang N, Smith ZR, Dorji T, Derado G, et al. Association of COVID-19 vaccination with symptomatic SARS-CoV-2 infection by time since vaccination and Delta variant predominance. JAMA. 2022;327(11):1032-41.  https://doi.org/10.1001/jama.2022.2068  PMID: 35157002 
  10. Lin D-Y, Gu Y, Xu Y, Wheeler B, Young H, Sunny SK, et al. Association of primary and booster vaccination and prior infection with SARS-CoV-2 infection and severe COVID-19 outcomes. JAMA. 2022;328(14):1415-26.  https://doi.org/10.1001/jama.2022.17876  PMID: 36155617 
  11. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):255-63.  https://doi.org/10.15585/mmwr.mm7107e2  PMID: 35176007 
  12. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med. 2022;386(4):340-50.  https://doi.org/10.1056/NEJMoa2115481  PMID: 35021002 
  13. Medicines and Healthcare products Regulatory Agency (MHRA). Regulatory approval of Spikevax bivalent Original/Omicron booster vaccine. London; MHRA; 2022. Available from: https://www.gov.uk/government/publications/regulatory-approval-of-spikevax-bivalent-originalomicron-booster-vaccine
  14. Medicines and Healthcare products Regulatory Agency (MHRA). Regulatory approval of Pfizer/BioNTech bivalent Original/Omicron booster vaccines. London; MHRA; 2022. Available from: https://www.gov.uk/government/publications/regulatory-approval-of-pfizerbiontech-bivalent-originalomicron-booster-vaccine
  15. Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, et al. A bivalent Omicron-containing booster vaccine against Covid-19. N Engl J Med. 2022;387(14):1279-91.  https://doi.org/10.1056/NEJMoa2208343  PMID: 36112399 
  16. Collier AY, Miller J, Hachmann NP, McMahan K, Liu J, Bondzie EA, et al. Immunogenicity of the BA.5 bivalent mRNA vaccine boosters. bioRxiv. 2022;2022.10.24.513619 . https://doi.org/10.1101/2022.10.24.513619 
  17. Wang Q, Bowen A, Valdez R, Gherasim C, Gordon A, Liu L, et al. Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot. bioRxiv. 2022;2022.10.22.513349 . https://doi.org/10.1101/2022.10.22.513349 
  18. Davis-Gardner ME, Lai L, Wali B, Samaha H, Solis D, Lee M, et al. mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1. bioRxiv. 2022;2022.10.31.514636 . https://doi.org/10.1101/2022.10.31.514636 
  19. Kurhade C, Zou J, Xia H, Liu M, Chang HC, Ren P, et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster. Nat Med. 2023;29(2):344-7. PMID: 36473500 
  20. United Kingdom Health Security Agency (UKHSA). England Summary. The official UK government website for data and insights on coronavirus (COVID-19). London: UKHSA. [Accessed: 24 Feb 2023]. Available from: https://coronavirus.data.gov.uk
  21. Andersson NW, Thiesson EM, Baum U, Pihlström N, Starrfelt J, Faksová K, et al. Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses. BMJ. 2023;382:e074325.  https://doi.org/10.1136/bmj-2022-074325  PMID: 37487623 
  22. United Kingdom Health Security Agency (UKHSA). SARS-CoV-2 variants of concern and variants under investigation in England: technical briefing 52. London: UKHSA; 2023. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1152143/variant-technical-briefing-52-21-april-2023.pdf
  23. Hyams C, Challen R, Begier E, Southern J, King J, Morley A, et al. Incidence of community acquired lower respiratory tract disease in Bristol, UK during the COVID-19 pandemic: A prospective cohort study. Lancet Reg Health Eur. 2022;21:100473.  https://doi.org/10.1016/j.lanepe.2022.100473  PMID: 35965672 
  24. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-81.  https://doi.org/10.1016/j.jbi.2008.08.010  PMID: 18929686 
  25. Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Lancet Infect Dis. 2021;21(11):1539-48.  https://doi.org/10.1016/S1473-3099(21)00330-3  PMID: 34174190 
  26. Joint Committee on Vaccination and Immunisation. JCVI statement on the COVID-19 booster vaccination programme for autumn 2022: update 3 September 2022. London: Department of Health and Social Care; 2022. Available from: https://www.gov.uk/government/publications/covid-19-vaccines-for-autumn-2022-jcvi-advice-15-august-2022/jcvi-statement-on-the-covid-19-booster-vaccination-programme-for-autumn-2022-update-15-august-2022
  27. European Centre for Disease Prevention and Control (ECDC). COVID-19 vaccine tracker. Stockholm: ECDC. [Accessed: 29 Jun 2023]. Available from: https://qap.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab
  28. Greenland S. Quantifying biases in causal models: classical confounding vs collider-stratification bias. Epidemiology. 2003;14(3):300-6.  https://doi.org/10.1097/01.EDE.0000042804.12056.6C  PMID: 12859030 
  29. Wellcome Sanger Institute. Lineages (raw). COVID-19 genomic surveillance. Cambridge: Wellcome Sanger Institute. [Accessed: 24 Feb 2023]. Available from: https://covid19.sanger.ac.uk/lineages/raw?p_type=line&area=E06000023&lineageView=1&lineages=A%2CB%2CB.1.177%2CB.1.1.529%2CBA.4%2CBA.5%2CBA.2&colours=7%2C3%2C0%2C6%2C2%2C4%2C1&show=B.1.1.529%2CBA.4%2CBA.5%2CBA.2
  30. Wright DW, Harvey WT, Hughes J, Cox M, Peacock TP, Colquhoun R, et al. Tracking SARS-CoV-2 mutations and variants through the COG-UK-Mutation Explorer. Virus Evol. 2022;8(1):veac023.  https://doi.org/10.1093/ve/veac023  PMID: 35502202 
  31. Hyams C, Challen R, Marlow R, Nguyen J, Begier E, Southern J, et al. Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom. Lancet Reg Health Eur. 2023;25:100556.  https://doi.org/10.1016/j.lanepe.2022.100556  PMID: 36530491 
  32. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303-12.  https://doi.org/10.1016/S0140-6736(22)00462-7  PMID: 35305296 
  33. Cerqueira-Silva T, Oliveira VA, Boaventura VS, Pescarini JM, Júnior JB, Machado TM, et al. Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study. Lancet Reg Health Am. 2022;6:100154.  https://doi.org/10.1016/j.lana.2021.100154  PMID: 34957437 
  34. United Kingdom Health Security Agency (UKHSA). COVID-19 vaccine surveillance report: week 5. London: UKHSA; 2023. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1134076/vaccine-surveillance-report-week-5-2023.pdf
  35. Chatzilena A, Hyams C, Challen R, Marlow R, King J, Adegbite D, et al. Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: A prospective test negative case-control study. Lancet Reg Health Eur. 2022;25:100552.  https://doi.org/10.1016/j.lanepe.2022.100552  PMID: 36506791 
Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case–control study, United Kingdom, 2022
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Anastasia+Chatzilena&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Chatzilena Anastasia</a>, <a href="/search?value1=Catherine+Hyams&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hyams Catherine</a>, <a href="/search?value1=Rob+Challen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Challen Rob</a>, <a href="/search?value1=Robin+Marlow&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Marlow Robin</a>, <a href="/search?value1=Jade+King&option1=author&noRedirect=true" class="nonDisambigAuthorLink">King Jade</a>, <a href="/search?value1=David+Adegbite&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Adegbite David</a>, <a href="/search?value1=Jane+Kinney&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kinney Jane</a>, <a href="/search?value1=Madeleine+Clout&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Clout Madeleine</a>, <a href="/search?value1=Nick+Maskell&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Maskell Nick</a>, <a href="/search?value1=Jennifer+Oliver&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Oliver Jennifer</a>, <a href="/search?value1=Adam+Finn&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Finn Adam</a>, <a href="/search?value1=Leon+Danon&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Danon Leon</a>, <a href="/search?value1=on+behalf+of+The+Avon+CAP+Research+Group&option1=author&noRedirect=true" class="nonDisambigAuthorLink">on behalf of The Avon CAP Research Group</a></span>. Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case–control study, United Kingdom, 2022. <a href="/content/ecdc">Euro Surveill.</a> 2023;28(48):pii=2300173. <a href="https://doi.org/10.2807/1560-7917.ES.2023.28.48.2300173" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2023.28.48.2300173</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 16 Mar 2023;&nbsp;&nbsp; <span class="generated">Accepted</span>: 27 Aug 2023 </span> </p>
/content/10.2807/1560-7917.ES.2023.28.48.2300173
/content/10.2807/1560-7917.ES.2023.28.48.2300173
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error